Indrayani Biotech reported a standalone net profit of ₹14.50 lakh for the quarter ended June 30, 2026, marking a 13.5% year-on-year increase compared to ₹12.77 lakh in the corresponding period last year.

The company’s revenue from operations stood at ₹415.34 lakh in Q1FY27, a significant decline of 37.9% from ₹668.57 lakh recorded in Q1FY26. Despite the drop in top-line performance, profitability improved due to lower employee benefit expenses and reduced finance costs relative to the previous year's comparable quarter.

Financial Performance Overview

The board meeting held on October 7, 2026, approved the unaudited standalone and consolidated financial results for the first quarter of FY27. The statutory auditors, Venkatesh & Co, issued an unmodified opinion on the standalone results.

Key financial metrics for the standalone entity are summarized below:

Consolidated Results

On a consolidated basis, Indrayani Biotech posted a net profit of ₹54.00 lakh for Q1FY27, a substantial improvement from the loss of ₹111.19 lakh incurred in the previous quarter (Q4FY26). Compared to Q1FY26, where consolidated profit was ₹15.65 lakh, the current quarter’s profit increased by 245%.

Consolidated revenue from operations rose to ₹3,770.55 lakh in Q1FY27, up 29.6% from ₹2,910.37 lakh in Q1FY26. The group’s total income reached ₹3,929.65 lakh, driven by higher operational revenue and other income contributions.

What the Numbers Show

A divergence exists between standalone and consolidated performance trends. While standalone revenue contracted sharply by 37.9% YoY, consolidated revenue expanded by 29.6%. This suggests that the group’s growth is being driven primarily by its subsidiaries rather than the parent entity. Additionally, the standalone net profit margin improved to 3.5% (from 1.9% in Q1FY26), aided by a significant reduction in employee benefit expenses, which fell from ₹150.15 lakh to ₹100.60 lakh YoY.

Board and Committee Updates

The Board also approved the reconstitution of several committees effective October 7, 2026:

• Audit Committee: Mr. Nangavaram Mahadevan Ranganathan (Chairman), Mr. Swaminathan Govindarajan, and Ms. Bokara Nagarajan Padmaja Priyadarshini.
• Stakeholder Relationship Committee: Same composition as the Audit Committee.
• Rights Issue Committee: Mr. Nangavaram Mahadevan Ranganathan (Chairman), Mr. Swaminathan Govindarajan, and Mr. Kasiraman Sayee Sundar.

Indrayani Biotech Limited completed the sale of 1.83% of its shareholding in subsidiary Dindigul Farm Product Limited on September 30, 2026. The transaction was executed through the open market, reducing Indrayani's stake in the entity to 27.05%.

The company filed an intimation with BSE under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirmed that the sale does not constitute a related party transaction and that no promoter or promoter group members hold any interest in the buyer entities.

Transaction details

The disposal involved shares of Dindigul Farm Product Limited, which reported a turnover of ₹90.04 crore (₹900,432,000) and paid-up capital of ₹24.43 crore (₹24,42,92,800). The subsidiary contributed 65.33% to the consolidated revenues during the last financial year.

What the numbers show

The divestment represents a marginal reduction in ownership while maintaining significant control. With the post-disposal stake standing at 27.05%, Indrayani Biotech retains a substantial equity position in Dindigul Farm Product Limited. Given that the subsidiary contributed 65.33% to revenues in the previous financial year, this minor dilution is unlikely to impact the parent company's consolidated top-line performance materially.